StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) company profile

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

About Kymera Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule therapeutics using targeted protein degradation. The company's technology engages cellular recycling machinery to selectively eliminate disease-causing proteins, particularly historically undrugged transcription factors and scaffolding proteins. Its pipeline centers on immunology programs, including KT-621 targeting STAT6 for inflammatory conditions such as atopic dermatitis and asthma, and KT-579 targeting IRF5 for autoimmune disorders. Kymera also advances partnered programs, including an IRAK4 degrader with Sanofi and cyclin-dependent kinase 2 molecular glue degraders with Gilead Sciences, alongside early-stage oncology research. The company targets patients suffering from immune-inflammatory diseases and cancers.

The company operates without internal manufacturing facilities, outsourcing the production of its drug substances and clinical products to third-party contract manufacturers on a purchase order basis. Kymera’s research and development initiatives address patient populations across the United States, Europe, and Japan. The provided text discusses collaborative agreements and clinical development across these regions, though it does not specify a headquarters location.

Summary of the business section of Kymera Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Kymera Therapeutics, Inc.
Headquarters
Watertown, MA
Address
500 North Beacon Street, 4th Floor 02472
Phone
(857) 285-5314
Employees
238, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
KYMR
Exchange
Nasdaq
IPO date
Aug 21, 2020
Shares outstanding
85M, Oct 23, 2026
Public float
$2.29B, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1815442
CUSIP
501575104
ISIN
US5015751044
FIGI
BBG00SDHC8D1
Share class FIGI
BBG00SDHC8F9
EIN
81-2992166

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Nello MainolfiChief Executive Officer, Director666,568
Brian AdamsChief Legal Officer50,254
Terence RooneyChief Medical Officer38,000
Noah GoodmanChief Business Officer47,179
Bruce N. JacobsChief Financial Officer248,083
Jeremy G. ChadwickChief Operating Officer44,618
Jared GollobChief Medical Officer117,134
Ellen ChiniaraChief Legal Officer82,326
Bruce BoothDirector2,396,426
Ii Gp Llc BvfDirector2,104,075
Value Fund L. P. BiotechnologyDirector2,104,075
Gp Holdings Llc BvfDirector–
Inc/Il BvfDirector2,195,696
I. Gp Llc BvfDirector294,632
Value Fund Ii Lp BiotechnologyDirector1,671,048
Mark N. LampertDirector2,494,688
Value Trading Fund OS LP BiotechnologyDirector2,350,503
Partners L. P/Il BvfDirector1,627,928
Partners OS Ltd. BVFDirector–
Jeffrey W. AlbersDirector5,000
Victor SandorDirector–
John MaraganoreDirector–
667, L.P.Director5,516,986
Elena RidloffDirector0
Bros. Advisors (GP) LLC BakerDirector6,117,295

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$8.55M$27.85M$3.77M$126$125
FY2024$15.43M$19.76M$5.37M$65$93
FY2023$9.67M$6.41M$4.40M$41$94
FY2022$6.93M-$24.97M$1.89M$40$90
FY2021$11.57M$12.61M$3.33M$102$100
FY2020$3.68M$30.95M$1.81M$186$115

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Nello Mainolfi
Founder, President and Chief Executive Officer
$693.00K–$7.32M$519.75K$14.00K$8.55M-45%
Bruce Jacobs
Chief Financial Officer
$500.00K$905.10K$1.20M$281.25K$14.00K$2.90M-59%
Jared Gollob
Chief Medical Officer
$507.10K$905.10K$1.20M$285.24K$14.00K$2.91M-49%
Noah Goodman
Chief Business Officer
$293.99K$1.05M$1.63M$181.73K$12.79K$3.17M–
Brian Adams
Chief Legal Officer
$145.18K$2.27M$3.56M$90.62K$6.26K$6.07M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 21, 2020
Offer price
$20.00
Securities offered
8,684,800
Gross proceeds
$173.70M
Exchange
Nasdaq
First trading day
Aug 21, 2020
First-day close
$33.26+66.3%
Lock-up ends (est.)
Feb 17, 2021

“The initial public offering price is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 238 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?